clinicalomicsprowebdirectory
Facebook
Linkedin
Twitter
News
Topics
Informatics
Molecular Dx
Patient Care
Oncology
Precision Medicine
Translational Research
Magazine
Browse Issues
Subscribe
Marketplace
Translational Research
Molecular Diagnostics
Oncology/Therapeutics
Healthcare Informatics
Subscribe
Get Inside Precision Medicine Magazine
Get Inside Precision Medicine eNewsletters
Multimedia
eBooks
Webinars
Summits
Learning Labs
Podcasts
Inside Precision Medicine Live
Search
Facebook
Linkedin
Twitter
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Create an account
Privacy Policy
Create an account
Welcome! Register for an account
your email
your username
A password will be e-mailed to you.
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
Inside Precision Medicine
News
News & Features
Infantile Fibrosarcoma and Other Solid Tumors Respond Well to Precision Medicine
News & Features
Dark Genome Sheds Light on How Emotions Can Lead to Addiction
News & Features
MRI Technique Detects Pre-Malignant Pancreatic Cancer Lesions
News & Features
Brain Tumors Hijack Circadian Rhythms to Accelerate Growth
News & Features
Microrobots Travel Deep Inside Body to Deliver Targeted Treatment
Topics
Informatics
Molecular Dx
Patient Care
Oncology
Precision Medicine
Translational Research
Magazine
Browse Issues
Subscribe
Marketplace
Translational Research
Molecular Diagnostics
Oncology/Therapeutics
Healthcare Informatics
Subscribe
Get Inside Precision Medicine Magazine
Get Inside Precision Medicine eNewsletters
Multimedia
eBooks
Webinars
Summits
Learning Labs
Podcasts
Inside Precision Medicine Live
Inside Precision Medicine
Terns Pharmaceuticals’ Allosteric Inhibitor Shows “Best-in-Class” Potential in Phase I CML Study
Phase I clinical trials (Drug development)
News & Features
Terns Pharmaceuticals’ Allosteric Inhibitor Shows “Best-in-Class” Potential in Phase I CML Study
Chris Anderson
December 4, 2024
0
News & Features
New Immune Cell Has Key Role in Anti-Tumor Immunity
October 30, 2024
0
News & Features
AviadoBio and Astellas Ink Potential $2.5B+ Deal for Frontotemporal Dementia Candidate
October 8, 2024
0
News & Features
Leapfrog Bio Screens Clinical Stage Drugs to Jump into Cancer Markets
Jonathan D. Grinstein, PhD
September 10, 2024
0
News & Features
Roche Oral GLP-1 Agonist Scores in Early Trial
July 19, 2024
0
News & Features
Vertex and Orum Launch $945M+ Collaboration to Replace Chemotherapy with DAC
July 17, 2024
0
News & Features
Microbiome Pill Could Boost Kidney Cancer Responses
July 1, 2024
0
News & Features
Metsera Launches with $290M to Develop Next Generation Weight Loss Products
April 22, 2024
0
News & Features
Investigational mRNA-Based Vaccine May Represent New Approach to Treating Pancreatic Cancer
April 8, 2024
0
News & Features
Gilead and Xilio Ink Potential $640M+ Deal around “Next-Generation” Immunotherapy
April 3, 2024
0
1
2
3
...
5
Page 1 of 5
Related Content
MRI Technique Detects Pre-Malignant Pancreatic Cancer Lesions
Daratumumab Reduces Risk of Progression in High-Risk Smoldering Multiple Myeloma Patients
The Importance of Increasing Diversity in Clinical Trials
Beam Therapeutics Sickle Cell Base Editing Works, Not Cause of Patient Death
Inside Precision Medicine
![Genomenon said today it has partnered with Rhythm Pharmaceuticals to create a database of genetic mutations associated with obesity as documented in published studies. Rhythm plans to use the data to better understand rare genetic disorders of obesity. [Visual Mozart/Getty Images]](https://www.insideprecisionmedicine.com/wp-content/uploads/2019/01/1628-768x794.jpeg "Metsera Launches with $290M to Develop Next Generation Weight Loss Products")
